PMC:7534795 / 112208-112421 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T75","span":{"begin":78,"end":86},"obj":"Body_part"}],"attributes":[{"id":"A75","pred":"fma_id","subj":"T75","obj":"http://purl.org/sig/ont/fma/fma62851"}],"text":" in healthy subjects, a higher recommended dose of n-3 PUFAs may be needed in platelet hyperactivity prothrombotic conditions such as in CVD (Adili et al., 2018). These anticoagulant properties of n-3 PUFAs sugges"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T137","span":{"begin":22,"end":23},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T138","span":{"begin":156,"end":160},"obj":"http://purl.obolibrary.org/obo/CLO_0001185"}],"text":" in healthy subjects, a higher recommended dose of n-3 PUFAs may be needed in platelet hyperactivity prothrombotic conditions such as in CVD (Adili et al., 2018). These anticoagulant properties of n-3 PUFAs sugges"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T6690","span":{"begin":55,"end":60},"obj":"Chemical"},{"id":"T85648","span":{"begin":169,"end":182},"obj":"Chemical"},{"id":"T53245","span":{"begin":201,"end":206},"obj":"Chemical"}],"attributes":[{"id":"A15654","pred":"chebi_id","subj":"T6690","obj":"http://purl.obolibrary.org/obo/CHEBI_26208"},{"id":"A48044","pred":"chebi_id","subj":"T85648","obj":"http://purl.obolibrary.org/obo/CHEBI_50249"},{"id":"A53592","pred":"chebi_id","subj":"T53245","obj":"http://purl.obolibrary.org/obo/CHEBI_26208"}],"text":" in healthy subjects, a higher recommended dose of n-3 PUFAs may be needed in platelet hyperactivity prothrombotic conditions such as in CVD (Adili et al., 2018). These anticoagulant properties of n-3 PUFAs sugges"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T252","span":{"begin":87,"end":100},"obj":"Phenotype"}],"attributes":[{"id":"A252","pred":"hp_id","subj":"T252","obj":"http://purl.obolibrary.org/obo/HP_0000752"}],"text":" in healthy subjects, a higher recommended dose of n-3 PUFAs may be needed in platelet hyperactivity prothrombotic conditions such as in CVD (Adili et al., 2018). These anticoagulant properties of n-3 PUFAs sugges"}

{"project":"2_test","denotations":[{"id":"33031856-30266534-84039146","span":{"begin":156,"end":160},"obj":"30266534"}],"text":" in healthy subjects, a higher recommended dose of n-3 PUFAs may be needed in platelet hyperactivity prothrombotic conditions such as in CVD (Adili et al., 2018). These anticoagulant properties of n-3 PUFAs sugges"}

{"project":"LitCovid-PubTator","denotations":[{"id":"3164","span":{"begin":51,"end":60},"obj":"Chemical"},{"id":"3165","span":{"begin":197,"end":206},"obj":"Chemical"},{"id":"3170","span":{"begin":87,"end":125},"obj":"Disease"},{"id":"3171","span":{"begin":137,"end":140},"obj":"Disease"}],"attributes":[{"id":"A3164","pred":"tao:has_database_id","subj":"3164","obj":"MESH:D015525"},{"id":"A3165","pred":"tao:has_database_id","subj":"3165","obj":"MESH:D015525"},{"id":"A3170","pred":"tao:has_database_id","subj":"3170","obj":"MESH:D006948"},{"id":"A3171","pred":"tao:has_database_id","subj":"3171","obj":"MESH:D002318"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" in healthy subjects, a higher recommended dose of n-3 PUFAs may be needed in platelet hyperactivity prothrombotic conditions such as in CVD (Adili et al., 2018). These anticoagulant properties of n-3 PUFAs sugges"}